<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324400</url>
  </required_header>
  <id_info>
    <org_study_id>PRNS003</org_study_id>
    <nct_id>NCT02324400</nct_id>
  </id_info>
  <brief_title>Pilot Study for the Evaluation of the Safety and Performance of the RenaSense System in Hospitalized Acute Decompensated Heart Failure Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nephera Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nephera Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to verify the safety and assess the performance of up to 3-days
      treatment protocol with the RenaSense System in ADHF patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with unanticipated adverse events as a measure of safety and tolerability</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Function as Assessed by Serum Cystatin C level</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms, hospitalizations and mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Assess no increase in urinary symptoms of obstruction or incontinence, hospitalizations and mortality rates following 30 days and 90 days follow-up, as compared to control with no electrical stimulation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Global Rank Score following 72 hours of treatment as compared to baseline</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
    <description>Urine output volume collected over 24 hour intervals during days 1 to 3 of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dosage of Furosemide administration</measure>
    <time_frame>72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dyspnea score as assessed by Likert scale</measure>
    <time_frame>72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fractional excretion of Sodium</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum brain natriuretic peptide (BNP) values following 48 and 72 hours of treatment</measure>
    <time_frame>48 and 72 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) following 72 hours of treatment as compared to baseline</measure>
    <time_frame>72 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Heart Decompensation</condition>
  <condition>Heart Failure, Congestive</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenaSense Stimulation</intervention_name>
    <description>RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenaSense Sham Control</intervention_name>
    <description>RenaSense Catheter,no delivery of stimulation</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females

          2. Age 18-85 years

          3. Admitted to the hospital with a primary diagnosis of decompensated heart failure

          4. Estimated glomerular filtration rate (GFR)* ≤60 ml/min and ≥20 ml/min, based on serum
             creatinine at initial evaluation

          5. History of chronic use of oral loop diuretics (≥ 80 mg/day Furosemide or equivalent)
             during the past 3 months

          6. Indication for treatment with intravenous diuretics

          7. Volume overload

             For patients with a pulmonary artery catheter, persistent volume overload will
             include:

               -  Pulmonary capillary wedge pressure greater than 22mmHg and one of the following
                  clinical signs:

               -  at least 2+ peripheral edema and/or

               -  Pulmonary edema or pleural effusions on chest x-ray

             For patients without a pulmonary artery catheter, persistent volume overload will
             include at least two of the following:

               -  At least 2+ peripheral edema

               -  Jugular venous pressure greater than 10 cm on physical examination (or central
                  venous pressure greater than 10 mmHg when measured)

               -  pulmonary edema or pleural effusions on chest x-ray

          8. Indication for urinary catheterization

          9. BNP &gt; 400 pg/mL at initial evaluation

         10. Able and willing to sign the informed consent

        Exclusion Criteria:

          1. History of urinary tract infection within the last 1 month based on medical history
             and/or urinalysis on day of admission

          2. Gross hematuria, perineal hematoma or symptomatic microscopic hematuria

          3. Hypertension, systolic &gt;180 mmHg or diastolic &gt; 110 mmHg

          4. Hypotension, systolic pressure &lt;100 mmHg

          5. Status post renal denervation

          6. Implanted cardiac rhythm management device such as pacemakers, cardiac
             resynchronization therapy (CRT), Implantable cardioverter-defibrillator (ICD)

          7. Suspected or known pregnancy

          8. Previous organ transplantation

          9. Life threatening condition such as severe infection, malignancy or infarction

         10. Subject is participating in other concurrent clinical investigation

         11. Diseases or conditions which, in the judgment of the investigator, preclude
             participation in the clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yotam Reisner, MD, PhD</last_name>
    <phone>+97246373797</phone>
    <email>yotam@nephera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <state>Outside USA</state>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hedera</city>
        <zip>3810101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

